CORONA Remedies Reports Strong Q1 FY27 Performance: PAT Up 30.1% YoY to ₹60.1 Crore

Ahmedabad-based branded pharmaceutical company CORONA Remedies Limited has announced its unaudited financial results for the first quarter ended June 30, 2026 (Q1 FY27). Driven by solid execution, brand-building initiatives, and improved operational efficiencies, the company achieved double-digit growth across both top-line revenue and bottom-line profitability.

Executive Summary & Financial Highlights

Revenue from Operations: Stood at ₹422.4 crore, marking a 21.9% year-over-year (YoY) increase compared to ₹346.5 crore in Q1 FY26.

EBITDA: Expanded by 33.5% YoY to ₹93.1 crore, up from ₹69.8 crore in Q1 FY26.

EBITDA Margin: Improved by 190 basis points (bps) YoY to 22.0%, compared to 20.1% in Q1 FY26.

Profit After Tax (PAT): Grew by 30.1% YoY to reach ₹60.1 crore, up from ₹46.2 crore in Q1 FY26.

PAT Margin: Stood at 14.2%, registering an expansion of 90 bps YoY from 13.3% in the corresponding prior-year period.

Operational Overview

The robust performance in Q1 FY27 reflects CORONA Remedies' continued focus on core growth drivers:

Brand Building: Accelerated focus on "engine brands" across key therapeutic categories.

Operational Excellence: Margin expansion driven by disciplined cost management and enhanced manufacturing and distribution efficiencies.

Commenting on the performance for Q1FY27, Mr. Nirav K. Mehta, Managing Director & CEO, CORONA Remedies Limited, said: "Q1 FY27 shows our commitment to consistent growth with operaonal excellence and brand building. With robustrevenue growth and market rank improvement, we see posive outcomes of the strategies in place.

We aim to move steadfast with our aligned focus on core therapies such as Women's Healthcare, Cardio-diabetes, Pain Management and Urology. We are also strengthening ourselves in Infertility and Biosimilar segment."

Shares of CORONA Remedies Limited was last trading in BSE at Rs. 2097.60 as compared to the previous close of Rs. 2089.65. The total number of shares traded during the day was 543 in over 121 trades.

The stock hit an intraday high of Rs. 2138.85 and intraday low of 2090.00. The net turnover during the day was Rs. 1145788.00.

Source : Equity Bulls

Keywords

CORONARemedies INE02ZQ01018 Pharmaceuticals Q1FY27 Q1FY2027 ResultUpdate